In recent decades, landmark trials of lipid-lowering therapies (LLT), including statins, ezetimibe, and proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, have demonstrated a reduction in both initial and recurrent ASCVD events. The gene discussed is PCSK9; the disease is atherosclerosis.